| Objective:To evaluate the clinical efficacy of Moschus Bezoar Pill combined with basic Western medicine treatment on acute coronary syndrome(ACS)patients with diabetes mellitus undergoing percutaneous coronary intervention(PCI),as well as its effects on traditional Chinese medicine syndrome score,cardiac function,lipid and glucose levels,major adverse cardiovascular and cerebrovascular events,and quality of life.Methods:102 ACS patients with diabetes mellitus who underwent PCI and were admitted to the Department of Cardiology of Subei People’s Hospital from October 1,2020 to June 30,2022 were selected as the study subjects.According to the different treatment methods,the 102 patients were divided into an observation group and a control group.Patients who received basic Western medicine treatment after surgery were allocated to the control group,while those who received Moschus Bezoar Pill in addition to the control group treatment were allocated to the observation group.Baseline characteristics including gender,age,smoking history,hypertension history,hyperlipidemia history,history of stroke,family history of coronary heart disease,heart rate,systolic blood pressure,diastolic blood pressure,body mass index,serum creatinine,ACS type,and number of coronary artery lesions were compared between the two groups.At 3 months after surgery,the clinical efficacy,traditional Chinese medicine syndrome score,cardiac function(including left ventricular ejection fraction,left ventricular end-diastolic diameter,N-terminal pro-brain natriuretic peptide),lipid levels(including total cholesterol,triglycerides,low-density lipoprotein cholesterol),blood glucose levels(including fasting blood glucose,glycated hemoglobin HbA1C),and quality of life score(SF-36 score)were collected and compared between the two groups.The patients were followed up for 270 days after surgery,and the occurrence of major adverse cardiovascular and cerebrovascular events(including recurrent angina pectoris,recurrent myocardial infarction,malignant arrhythmia,new-onset heart failure,new-onset stroke,and cardiovascular death)was collected and compared between the two groups.Results:1.The baseline data of the two patient groups,including gender,age,smoking history,hypertension history,hyperlipidemia history,history of stroke,family history of coronary heart disease,heart rate,systolic blood pressure,diastolic blood pressure,body mass index,blood creatinine,type of acute coronary syndrome,and number of coronary artery lesions,showed no statistically significant differences between the groups(P>0.05).2.The total effective rate in the observation group was significantly higher than that in the control group(92.2%vs 76.5%),and the difference was statistically significant(P<0.05).3.The traditional Chinese medicine syndrome score in the observation group was significantly lower than that in the control group(8.61±10.24 vs 12.76±9.25),and the difference was statistically significant(P<0.05).4.Before treatment,there was no significant difference in cardiac function indicators between the two groups(P>0.05).After treatment,both groups showed an improvement in left ventricular ejection fraction(LVEF),and a decrease in left ventricular end-diastolic diameter(LVEDD)and NT-proBNP,with the improvement in LVEF being more significant in the observation group than in the control group(58.34±6.73 vs 54.69±5.41).The2 decrease in LVEDD and NT-proBNP was also more significant in the observation group than in the control group(48.07±3.96 vs 46.23±4.12,334.25±80.98 vs 372.46±75.55),and the differences were statistically significant(P<0.05).5.Before treatment,there was no significant difference in lipid levels between the two groups(P>0.05).After treatment,both groups showed a significant decrease in total cholesterol(TC),triglycerides(TG),and low-density lipoprotein(LDL),with the decrease in TC,TG,and LDL being more significant in the observation group than in the control group(3.95±0.50 vs 4.23±0.72,1.69±0.54 vs 1.98±0.62,2.16±0.65 vs 2.54±0.76),and the differences were statistically significant(P<0.05).6.Before treatment,there was no significant difference in blood glucose levels between the two groups of patients(P>0.05).After treatment,both groups showed significant reductions in FPG and HbA1C levels.The degree of FPG reduction in the observation group was similar to that in the control group(6.05±1.11 vs 6.44±1.32),and the difference was not statistically significant.However,the degree of HbAlC reduction in the observation group was significantly greater than that in the control group(7.02±0.78 vs 7.38±0.85),and the difference was statistically significant(P<0.05).7.The SF-36 scores of the observation group in the eight dimensions of physical functioning,physical role functioning,mental health,emotional role functioning,bodily pain,vitality,social functioning,and general health were higher than those of the control group,and the difference was statistically significant(P<0.05).8.The probability of major cardiovascular and cerebrovascular adverse events in the observation group was significantly lower than that in the control group(21.65%vs 37.25%),and the difference was statistically significant(P<0.05).There was no statistically significant difference in the incidence of individual events such as recurrent angina,recurrent myocardial infarction,malignant arrhythmia,new-onset heart failure,stroke,and cardiovascular death between the two groups(P>0.05).The two groups had no-event survival rates,and the difference was not statistically significant(P>0.05).Conclusion:The combination of Musk Pill for Treating Heart Disease and Western medicine can effectively improve the clinical symptoms and TCM syndrome of patients with acute coronary syndrome and diabetes undergoing PCI,improve patients’ heart function,blood glucose,and lipid levels,reduce the incidence of major cardiovascular and cerebrovascular adverse events,and improve their postoperative quality of life. |
PDF Full Text Request